Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IH636 grape seed proanthocyanidin extract is a standardized extract from the seeds of *Vitis vinifera* containing oligomeric proanthocyanidins (OPCs), a class of polyphenolic flavonoids. It is recognized for its potent **antioxidant**, **free-radical scavenging**, and **chemoprotective properties**. IH636 has shown the ability to inhibit the growth of certain cancer cells while promoting the viability of normal cells[1][4][6]. Mechanistically, its effects are proposed to involve scavenging of free radicals, inhibition of lipid peroxidation and DNA fragmentation, and modulation of apoptotic and survival gene expression (including upregulation of bcl-Xs and JNK, and downregulation of bcl-Xl)[1][4]. It has demonstrated cardioprotective effects, including reduction of atherosclerotic lesions and serum cholesterol in animal models, and may reduce oxidative stress-mediated vascular injury[2][4][5]. Clinical studies and dietary supplement monographs describe use for symptoms of chronic venous insufficiency and as a general antioxidant[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IH636 grape seed proanthocyanidin extract.